CORDIS
EU research results

CORDIS

English EN

Investigating Mechanisms and Models Predictive of Accessibility of Therapeutics (IM2PACT) Into The Brain

Objective

The overall aim is to further the understanding of the BBB in health and disease states towards the development of innovative brain delivery systems, especially for biopharmaceuticals (e.g., peptides, antibodies, etc.) and the identification of novel disease drug targets (Alzheimer’s Disease, MS, metabolic disease). The related key deliverables will be as follows:

1.Identification and validation of specific genes and/or mechanisms which are altered in brain endothelial cells in disease.
2. Generation, validation and characterisation of robust and predictive iPSC-derived BBB models: The developed models should be more reflective of the in vivo situation than existing models, in the healthy and disease states.
3. New, efficacious and safe mechanisms and technologies of brain delivery: The output of this topic should also result in an expanded and deepened understanding of the fundamental processes that underpin drug-trafficking across the BBB, which in turn can further support endeavours to elucidate novel and more efficacious brain delivery mechanisms.
4. Characterised new genetic models for the diseases of interest in this topic which are better amenable to evaluate disease-modifying agents.
5. Characterised mechanisms of neurotropic virus-mediated BBB and CNS penetration for development of selective brain delivery systems.
6. Established in silico/mathematical models in predicting BBB penetration of therapeutics (such as receptor-or carrier-mediated transcytosis for delivery across the BBB) and pharmacokinetics of biopharmaceutics in different compartments of CNS.
7. Identification of relevant translational readouts which are better amenable to elucidate the role of the BBB in the pathogenesis of neurodegeneration and could eventually lead to new targets for the treatment of the neurovascular causes of the diseases.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

Address

Wellington Square University Offices
Ox1 2jd Oxford

United Kingdom

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 2 462 486,25

Participants (26)

Sort alphabetically

Sort by EU Contribution

Expand all

UPPSALA UNIVERSITET

Sweden

EU Contribution

€ 1 113 250

STICHTING VUMC

Netherlands

EU Contribution

€ 290 437,50

UNIVERSITY OF DUNDEE

United Kingdom

EU Contribution

€ 354 008,75

ACADEMISCH ZIEKENHUIS LEIDEN

Netherlands

EU Contribution

€ 297 500

KOBENHAVNS UNIVERSITET

Denmark

EU Contribution

€ 532 198,75

AARHUS UNIVERSITET

Denmark

EU Contribution

€ 483 966,25

UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAET MAINZ

Germany

EU Contribution

€ 288 661,25

RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG

Germany

EU Contribution

€ 290 187,50

AIT AUSTRIAN INSTITUTE OF TECHNOLOGY GMBH

Austria

EU Contribution

€ 582 292,50

MIMETAS BV

Netherlands

EU Contribution

€ 251 812,50

THE OPEN UNIVERSITY

United Kingdom

EU Contribution

€ 232 283,75

UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT

Germany

EU Contribution

€ 213 718,75

STIFTUNG TIERAERZTLICHE HOCHSCHULE HANNOVER

Germany

EU Contribution

€ 290 312,50

ARTEMIS BIO-SUPPORT B.V.

Netherlands

EU Contribution

€ 290 380

NEUWAY PHARMA GMBH

Germany

EU Contribution

€ 112 500

THE UNIVERSITY OF SHEFFIELD

United Kingdom

EU Contribution

€ 249 305

UNIVERSITA DEGLI STUDI DI MODENA E REGGIO EMILIA

Italy

EU Contribution

€ 67 565

PHARMACOIDEA FEJLESZTO ES SZOLGALTATO KFT

Hungary

EU Contribution

€ 300 058,75

CARDIFF UNIVERSITY

United Kingdom

EU Contribution

€ 297 075

SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT

France

PFIZER LIMITED

United Kingdom

NOVARTIS PHARMA AG

Switzerland

NOVO NORDISK A/S

Denmark

FUJIFILM CELLULAR DYNAMICS INC

United States

JANSSEN PHARMACEUTICA NV

Belgium

H. LUNDBECK AS

Denmark

Project information

Grant agreement ID: 807015

Status

Ongoing project

  • Start date

    1 January 2019

  • End date

    31 December 2023

Funded under:

H2020-EU.3.1.7.

  • Overall budget:

    € 17 410 136

  • EU contribution

    € 9 000 000

Coordinated by:

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

United Kingdom